Depemokimab vs Mepolizumab

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

NCT01463644 · Phase 3 · completed

Participants were randomly assigned and quadruple-blinded to mepolizumab or placebo, but only 18 people were enrolled. The primary endpoint was a sputum eosinophil biomarker rather than a clinical outcome, and the registry does not state whether the between-group difference was statistically significant, so the result is unclear.

NCT04718389 · Phase 3 · completed

This was a large randomized, double-blind, active-controlled trial comparing depemokimab with mepolizumab or benralizumab, using the clinically meaningful primary endpoint of annualized clinically significant asthma exacerbations. The primary results were 0.57 versus 0.49 exacerbations per participant-year (rate ratio 1.16, 95% CI 0.98–1.38; p=0.079), but the record does not provide the non-inferiority margin, so it is not possible to confirm that the primary endpoint was met.

NCT01691859 · Phase 3 · completed

This was an open-label, single-arm long-term extension of the prior MEA112997 trial, enrolling 347 participants who had received at least two doses in that study. Because there was no randomization, blinding, or control group, the primary safety endpoint was descriptive rather than a comparative efficacy test, although the explicit extension design provides follow-up evidence beyond the original randomized trial.